News and Trends 18 Jan 2017 New Combo Therapy for Type 2 Diabetes to Sweep Europe Zealand Pharma and its partner Sanofi have made it to the European market with a new combination therapy to treat type 2 diabetes. Suliqua, a treatment for type 2 diabetes, has received marketing authorization in Europe. This feat has earned Zealand Pharma a €9.4M ($10M) payment from its partner Sanofi. The big pharma is responsible […] January 18, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 26 Dec 2016 The Largest Deals, Fundraising and Exits of 2016 in European Biotech Curious about which technologies have attracted the most cash in biotech finance this year? Here’s a list of the most impressive cash movements of 2016 in Europe. Believe it or not, 2016 has been the worst year for biotech finance in a decade. The political scene has become unfavorable for British biotech after Brexit, and the uncertainty raised by […] December 26, 2016 - 5 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 23 Dec 2016 The 8 Biggest Biotech Medical Fails of 2016 in Europe Although 2016 has brought plenty of good news in medical advances, biotech is an industry where failure is part of the game. Here’s a list of medical fails in biotech to learn from this year. Unfortunately, 2016 has not been a good year for pharma, with revenues in the top companies falling, the lowest number […] December 23, 2016 - 5 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 19 Dec 2016 How is Biotech responding to Patient Advocacy in Rare Disease? A panel of experts in rare disease discussed some of the latest trends at Labiotech Refresh, focusing on the growing patient involvement and how it is benefiting this field. Rare diseases are attracting biotech and pharma more and more since they are typically less crowded areas with unmet clinical needs. However, the lower numbers of […] December 19, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 6 Dec 2016 Sanofi Jumps into the Biosimilars Market aiming for Asia Sanofi is joining the biosimilars trend to challenge Roche’s best-selling biological with a partnership that aims to take over the Chinese cancer market. Sanofi is going after the €6.8B ($7.3B) that Roche’s Rituxan/MabThera (rituximab), the second top-selling biological, made last year in revenues. The French pharma has signed a deal worth up to €219M ($236M) […] December 6, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 1 Dec 2016 UPDATE: The HIV Frontier starts Phase III Vaccine trials in South Africa Update (01/12/2016): The HVTN 702 trial has been started, making it the first HIV vaccine efficacy study in 7 years worldwide. Results are expected in late 2020. Originally published 25/07/2016 A Phase IIb/III trial for an experimental HIV vaccine just started in South Africa. The therapy, co-funded by the NIH and the Gates Foundation, is a combination […] December 1, 2016 - 3 minutesmins - By Denise Neves Gameiro Share WhatsApp Twitter Linkedin Email
News and Trends 22 Nov 2016 Sanofi quietly leaves Bladder Cancer Patients in the lurch Sanofi is halting the production of the main bladder cancer drug. In response, doctors are pressuring regulatory agencies to take action against this instance of a widespread issue of drug shortages. Sanofi Pasteur announced last week that it will be shutting down the production of the cancer drug BCG (TheraCys and ImmuCyst) in mid-2017. This drug […] November 22, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 15 Nov 2016 RNAi Therapy is Back: Sanofi is firmly on board to treat Hemophilia Sanofi Genzyme is offering Alnylam up to €93M ($100M) to co-develop and launch a revolutionary RNAi therapy for hemophilia. But is RNAi really such a good investment? Sanofi Genzyme signed a deal with Alnylam back in 2014 to develop RNAi therapies. Now, despite the general discouragement in RNAi technology, Sanofi has decided to go ahead and […] November 15, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 7 Nov 2016 Results from 45% of Clinical Trials are kept Secret A new transparency study has identified Sanofi, Novartis and GSK as the companies that keep the most clinical trial results unreported. TrialsTracker is a tool developed at the University of Oxford that automatically rates transparency on clinical trials by checking if there are results available in clinicaltrials.gov and PubMed. The results: globally, 45% of data on […] November 7, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 11 Feb 2016 Sanofi-Genzyme: Still successful 5 years after the acquisition? Back in 2011, France’s biggest Pharmaceutical company Sanofi decided to purchase Genzyme Corp. for more than $20 billion, thus becoming the latest global drug giant to acquire a big biotech to foster its R&D pipeline. 5 years later, what’s the situation for Genzyme and Sanofi? So often when a large Pharma acquires a smaller Biotech, […] February 11, 2016 - 3 minutesmins - By Dani Bancroft Share WhatsApp Twitter Linkedin Email
News and Trends 20 Apr 2015 So, what is actually Biotech? Biotechnology is a broad domain, which includes numerous areas such as healing, feeding and fueling the world. Historically-speaking, the biotech sector started in the 80s with the discovery of gene cloning. The first “Biotech” ever born was Genentech (contraction of Gene and Technology), founded in South San Francisco, which successfully produced human insulin in bacteria. The Organisation […] April 20, 2015 - 4 minutesmins - By Nicolas Sainte-Foie Share WhatsApp Twitter Linkedin Email